Kintor Pharmaceutical Limited (09939.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.0x

Market Cap

HKD 840.12M

MomentumView details →

1D Return

−3.96%

YTD Return

−7.14%

RSI (14)

52.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.0x

Market Cap

HKD 840.12M

RSI (14)

52.5

MomentumView details →

1D Return

−3.96%

YTD Return

−7.14%

ProfitabilityView details →

Gross Margin

16.92%

Net Margin

−404.93%

EBITDA Margin

−310.85%

ROE (TTM)

−331.60%

ROA (TTM)

−113.56%

Asset Turnover

0.27x

GrowthView details →

Revenue YoY

—

EPS YoY

+79.23%

FCF YoY

—

Revenue CAGR 3Y

+553.64%

EPS CAGR 3Y

−22.22%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.18

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.22x

Current Ratio

0.26x

Quick Ratio

0.20x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

89.43M

Net Income (TTM)

−362.12M

Op. CF (TTM)

−319.41M

Next earningsApr 1, 2027 →

Latest newsMore news →

Kintor Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 52.04 million, up about 7.7 times year-on-year, and a narrowed net loss of RMB 75.782 million from RMB 83.268 million a year earlier.16d ago

Similar companies

DBV Technologies S.A.DBVT 4D Molecular Therapeutics, Inc.FDMT Pharming Group N.V.PHAR CANbridge Pharmaceuticals Inc.01228.HK Achieve Life Sciences, Inc.ACHV JW (Cayman) Therapeutics Co. Ltd02126.HK Find similar companies →

Latest newsMore news →

Kintor Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 52.04 million, up about 7.7 times year-on-year, and a narrowed net loss of RMB 75.782 million from RMB 83.268 million a year earlier.16d ago